Tag Archives: Advancement In Cancer Treatment

New Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors

Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors
Three-Part Molecule May Decrease Growth of Certain Types of Cancer Tumors

If one is good and two is better, is three the answer? Scientists are hoping that a new three-part molecule could be an answer regarding effective immuno oncology for breast cancer patients.

Stemming the Growth of Breast Cancer Cells

Approximately 20 to 30 percent of breast cancer cases involve over-expression of HER2, which is a growth factor that leads to aggressive multiplication of cancer cells. This acceleration often makes these types of cancer resistant to therapy, resulting in poor prognoses.

Dr. Hongyan Liu, a bioengineer at the Georgia Cancer Center, led a team that developed a chimera, or three-part molecule, to suppress the growth factors. The chimera targets HER2, HER3 and EGFR because one member of the HER “family” can compensate when another one is blocked.

Exploring the Abilities of the Three-Part Molecule

The new molecule is non-toxic, easy to manufacture and relatively cost-effective, making scientists optimistic about its value for immuno oncology. Dr. Liu and her team are currently conducting studies to determine if the chimera can treat cancer that is resistant to Herceptin, a drug that inhibits HER2.

Breast cancer is not the only form that grows due to over-expression of HER receptors. Dr. Liu is hopeful that the chimera will have future applications for lung, head and neck cancers as well.

Issels®: The Leader in Personalized Immuno Oncology Treatments

Our non-toxic immuno oncology programs have been successful in treating therapy-resistant cases of breast cancer and other forms. Contact us today to learn more about how we are carrying on the legacy of our founder, Dr. Josef M. Issels, who predicted the future of immunotherapy.

Protein Blocking May Play a New Role in New Testicular Cancer Treatment

Protein Blocking May Play a New Role in New Testicular Cancer Treatment
Protein Blocking May Play a New Role in New Testicular Cancer Treatment

What options does a patient have when traditional forms of cancer treatment fail? In the case of testicular cancer, scientists found a new combination of treatments that may provide added hope.

Overcoming Resistance to Cancer Treatment

Testicular germ cell tumors are a form of cancer found most commonly in younger men. A research team at the Institute of Cancer Research in London, encouraged by earlier work at the facility, examined the function of a certain type of protein in the development of testicular cancer.

The team focused specifically on insulin growth factor receptor-1. They discovered that IGF1R, as the protein is also called, was more active in some testicular cancer cells as opposed to normal tissue. Using chemical inhibitors, the researchers were able to deplete the supply of IGF1R or curtail its activity, thereby reducing cell growth.

In addition, blocking IGF1R activity in previously drug-resistant cells made them more receptive to platinum-based chemotherapy. The team is hopeful that the two treatments, used in tandem, will be more successful in killing testicular cancer cells.

What Does the Future Hold?

Receptor tyrosine kinases, the class of proteins that includes IGF1R, are linked to cell growth and division in several other types of cancer. Clinical trials have tested the use of IGF1R in hopes that they may have positive results in other applications.

Effective Cancer Treatment for Therapy-Resistant Tumors

For decades, Issels® has been helping patients with advanced and therapy-resistant cancer achieve long-term remission. Contact us to learn how we are continuing the legacy of our founder, Dr. Josef M. Issels, who was a pioneer in the field of immunotherapy for cancer.

One in five US Cancer Patients Are Diagnosed with a Rare Cancer

1 in 5 US Cancer Patients Are Diagnosed with a Rare Cancer
1 in 5 US Cancer Patients Are Diagnosed with a Rare Cancer

Rare cancers are more common than you think. As a group, they make up about 20% of all cancer diagnoses. However, each specific type of rare cancer is still very dangerous because the symptoms are often misdiagnosed. At Issels®, we often see patients whose rare cancer went undiagnosed despite several rounds of doctor visits and tests.

The American Cancer Society recently shed light on the frequency of rare cancer diagnoses:

  • Rare cancer is defined by annual diagnoses in less than 6 out of 100,000 people
  • 71% of all cases in people under 20 years old are rare types
  • 39% of all cases in people 20 to 39 years old are rare types
  • Younger people have better survival rates for rare cancer than older people

Together, Learning More About Rare Cancers

In some cases, standard cancer treatment fails to work as well as it does for common types of cancer. On the other hand, the ACS notes that innovations in rare cancer treatment often help scientists develop better treatment for all types of cancers.

After a rare cancer diagnosis, it can be difficult to find information if your physicians are not very familiar with the disease. We specialize in advanced stage cancer treatment at Issels®, including rare types of the disease that are not responding well enough to standard therapies.

At Issels®, we offer individualized treatments including cancer vaccines developed using the patient’s own autoimmune cells. Such treatments, known as immunotherapy, are helping patients with standard therapy–resistant and advanced stages of cancer.

Learn more about our integrative immunotherapy approach to cancer treatment on our website or contact us for more info.

Immunotherapy: A Doctor’s Fundamental Change in Treating Cancer

Using the Body to Fight Cancer
Using the Body to Fight Cancer

Traditional cancer treatments such as chemotherapy and radiation are directed at fighting tumors head-on. Immunotherapy for cancer, which is aimed at making the body’s immune system more effective against tumors, has created a fundamental change in the way doctors approach treatment.

A Long-Held “Medical Dream” Becomes Reality

While the earliest attempts at immunotherapy date back more than 100 years, it presented too much of a puzzle to doctors. As a result, radiation and chemotherapy surpassed immunotherapy as the treatments of choice for cancer.

As modern research with immunotherapy uncovered more effective methods with documented track records, medical and financial floodgates have opened. Charitable organizations, pharmaceutical companies and the federal government are dedicating billions of dollars to fund hundreds of trials involving various treatments on every type of cancer.

Boosting the Body’s Own Immune System

While there is still much to learn, researchers are focusing primarily on two types of immunotherapy for cancer:

  • In the first method, a doctor removes some of the patient’s own immune cells and creates genetic alterations enabling them to attack cancer cells, at which point they are added back to the bloodstream.
  • The second method makes use of drugs known as checkpoint inhibitors, which block the mechanism used by cancer cells to evade detection and attack by the immune system.

Issels®: Leading the Way in Immunotherapy for Cancer

Our immunotherapy center has continued the groundbreaking work of our founder, Dr. Josef M. Issels, using state-of-the-art therapies to treat patients with all forms of cancer. Contact us today to learn more about our non-toxic treatments such as cancer vaccines and NK cells.

 

Big Pharma Criticized for Standing in the Way of New Cancer Treatments

Big Pharmasudical Problems
Big Pharmasudical Problems

“It is time for drug companies to put helping patients first,” says Dr. Carlos S. Moreno. The Associate Professor of Pathology and Laboratory Medicine and Biomedical Informatics at Emory University makes a compelling argument on Reuters.com that it’s time large pharmaceutical companies started living up to their stated goal of saving and improving lives. By placing their responsibilities to their shareholders and profit margin over their moral responsibility to better patients’ lives, Moreno says Big Pharma is holding back vital cancer research.

At issue are the roadblocks cancer researchers are encountering as they explore new avenues for treating cancer. As Moreno notes, “Researchers … are making remarkable discoveries to help identify new drugs and drug targets for cancer patients. Many new compounds are under investigation, including those that inhibit the growth of cancer cells, block the blood supply to tumors and prevent tumors from evading the immune system.”

The sequencing of cancer genomes has allowed the development of advanced targeted therapies and is providing researchers with new insights into how cancer grows and why it returns. As Moreno explains:

“One clear insight we have gained is the likelihood that no single drug will be able to defeat cancer. The reason most cancers become drug resistant and come back is because the DNA mutates quickly. Cancer cells that are not killed by the drugs survive, continue to grow and replace the cells that have been wiped out.”

Many cancer researchers have concluded that an integrative approach to cancer treatment is necessary to defeat cancer’s ability to mutate and survive. Unfortunately, researchers are finding that their ability to turn new discoveries into therapeutic cancer treatments is being stymied by Big Pharma’s constant eye on profit margins.

To be continued